Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Ltd is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. It has operations in India and caters to both domestic and international markets.
What Jagsonpal files
- Others57
- Important36
- Investor Meet36
- Updates18
- Dividend/Bonus9
- Board Meeting7
Jagsonpal Pharma approved granting 1,20,000 Employee Stock Options at an exercise price of Rs. 179.25 per option. These options will vest in 4 equal annual tranches, potentially impacting future equity.
Jagsonpal Pharma reported strong Q1 FY27: Revenue +9%, PAT +22%, Op. EBITDA +21%. It acquired 85% of Aequitas Healthcare for ₹20.8 Cr, entering hospital supplies and targeting ₹10 Cr EBITDA post-integration. Cash reserves remain robust at ₹170 Cr despite a ₹40 Cr share buyback.
Jagsonpal Pharma acquires 85% of Aequitas Healthcare for Rs. 20.8 Cr, funded internally. This strategic move establishes Jagsonpal in the hospital segment, leveraging Aequitas's Rs. 53 Cr FY26 revenue for omnichannel expansion.
Jagsonpal Pharma acquires 85% of Aequitas Healthcare for 20.8 Cr, strategically entering the hospital segment. This move leverages Aequitas's established hospital network and 53.31 Cr FY26 revenue, aiming to boost Jagsonpal's market presence and diversify its healthcare business.
Jagsonpal Pharma appointed industry veteran Anil Kumar Matai as an Independent Director. Matai brings 30+ years of pharma/healthcare leadership, aiming to drive strategic growth and strengthen performance for the company.